These findings reveal novel mechanisms through which glioma cells modulate the immunosuppressive microenvironment and highlight TPST1 as a potential therapeutic target associated with T-cell exclusion and poor immunotherapy response mechanisms, though further validation in glioma-specific cohorts is required. Here, TPST1 is linked to central nervous system cancer.